...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith AGM Corporation Update Slides and Webcast

narmac, I'm in your camp completely. There is no reason why shareholders should be held hositage on the liquidity issue.

I do agree with Mazola that the science seems to be progressing well but it will be a very long journey through to various phase 3 trials and then possible success or back to the drawing board.

I got the impression that perhaps zen3694 could get approval in China sooner.

Also I get the impression that there may be a close enough relationship with some partners for a buyout at some point but having discussed CVRs on the RVX business I doubt that that will happen soon.

I really can't argue in any way with the scientific progress and results other than Zenith is not keeping us updated enough.

However, to be held hostage on liquidity is not acceptable for me. I'm sure Don must be relieved again because he does not have to face shareholders for another year and he has made no commitments that I can see. 

GLTA

Toinv

Share
New Message
Please login to post a reply